<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">30523750</PMID>
      <DateCompleted>
        <Year>2019</Year>
        <Month>10</Month>
        <Day>29</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2019</Year>
        <Month>10</Month>
        <Day>29</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1527-7755</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>37</Volume>
            <Issue>3</Issue>
            <PubDate>
              <Year>2019</Year>
              <Month>Jan</Month>
              <Day>20</Day>
            </PubDate>
          </JournalIssue>
          <Title>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</Title>
          <ISOAbbreviation>J Clin Oncol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor-Positive Early Breast Cancer: PALLET Trial.</ArticleTitle>
        <Pagination>
          <StartPage>178</StartPage>
          <EndPage>189</EndPage>
          <MedlinePgn>178-189</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1200/JCO.18.01624</ELocationID>
        <Abstract>
          <AbstractText Label="PURPOSE">CDK4/6 inhibitors are used to treat estrogen receptor (ER)-positive metastatic breast cancer (BC) in combination with endocrine therapy. PALLET is a phase II randomized trial that evaluated the effects of combination palbociclib plus letrozole as neoadjuvant therapy.</AbstractText>
          <AbstractText Label="PATIENTS AND METHODS">Postmenopausal women with ER-positive primary BC and tumors greater than or equal to 2.0 cm were randomly assigned 3:2:2:2 to letrozole (2.5 mg/d) for 14 weeks (A); letrozole for 2 weeks, then palbociclib plus letrozole to 14 weeks (B); palbociclib for 2 weeks, then palbociclib plus letrozole to 14 weeks (C); or palbociclib plus letrozole for 14 weeks. Palbociclib 125 mg/d was administered orally on a 21-days-on, 7-days-off schedule. Core-cut biopsies were taken at baseline and 2 and 14 weeks. Coprimary end points for letrozole versus palbociclib plus letrozole groups (A v B + C + D) were change in Ki-67 (protein encoded by the  MKI67 gene; immunohistochemistry) between baseline and 14 weeks and clinical response (ordinal and ultrasound) after 14 weeks. Complete cell-cycle arrest was defined as Ki-67 less than or equal to 2.7%. Apoptosis was characterized by cleaved poly (ADP-ribose) polymerase.</AbstractText>
          <AbstractText Label="RESULTS">Three hundred seven patients were recruited. Clinical response was not significantly different between palbociclib plus letrozole and letrozole groups ( P = .20; complete response + partial response, 54.3% v 49.5%), and progressive disease was 3.2% versus 5.4%, respectively. Median log-fold change in Ki-67 was greater with palbociclib plus letrozole compared with letrozole (-4.1 v -2.2; P &lt; .001) in the 190 evaluable patients (61.9%), corresponding to a geometric mean change of -97.4% versus -88.5%. More patients on palbociclib plus letrozole achieved complete cell-cycle arrest (90% v 59%; P &lt; .001). Median log-fold change (suppression) of cleaved poly (ADP-ribose) polymerase was greater with palbociclib plus letrozole versus letrozole (-0.80 v -0.42; P &lt; .001). More patients had grade 3 or greater toxicity on palbociclib plus letrozole (49.8% v 17.0%; P &lt; .001) mainly because of asymptomatic neutropenia.</AbstractText>
          <AbstractText Label="CONCLUSION">Adding palbociclib to letrozole significantly enhanced the suppression of malignant cell proliferation (Ki-67) in primary ER-positive BC, but did not increase the clinical response rate over 14 weeks, which was possibly related to a concurrent reduction in apoptosis.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Johnston</LastName>
            <ForeName>Stephen</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>1 The Royal Marsden National Health Service Foundation Trust, London, United Kingdom.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Puhalla</LastName>
            <ForeName>Shannon</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>2 Univeristy of Pittsburgh Medical Center Cancer Center, Pittsburgh, PA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wheatley</LastName>
            <ForeName>Duncan</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>3 Royal Cornwall Hospitals National Health Service Foundation Trust, Treliske, United Kingdom.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ring</LastName>
            <ForeName>Alistair</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>1 The Royal Marsden National Health Service Foundation Trust, London, United Kingdom.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Barry</LastName>
            <ForeName>Peter</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>1 The Royal Marsden National Health Service Foundation Trust, London, United Kingdom.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Holcombe</LastName>
            <ForeName>Chris</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>4 Royal Liverpool and Broadgreen University Hospitals National Health Service Trust, Liverpool, United Kingdom.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Boileau</LastName>
            <ForeName>Jean Francois</ForeName>
            <Initials>JF</Initials>
            <AffiliationInfo>
              <Affiliation>5 Montreal Jewish General Hospital Segal Cancer Centre, Montreal, Quebec, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Provencher</LastName>
            <ForeName>Louise</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>6 Centre Hospitalier Université de Quebec-Universite Laval, Quebec City, Quebec, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Robidoux</LastName>
            <ForeName>André</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>7 Centre Hospitalier Université de Montréal, Montreal, Quebec, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Rimawi</LastName>
            <ForeName>Mothaffar</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>8 Baylor College of Medicine, Houston, TX.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>McIntosh</LastName>
            <ForeName>Stuart A</ForeName>
            <Initials>SA</Initials>
            <AffiliationInfo>
              <Affiliation>9 Queen's University Belfast, Belfast, United Kingdom.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shalaby</LastName>
            <ForeName>Ibrahim</ForeName>
            <Initials>I</Initials>
            <AffiliationInfo>
              <Affiliation>10 Joe Arrington Cancer Research and Treatment Center, Lubbock, TX.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Stein</LastName>
            <ForeName>Robert C</ForeName>
            <Initials>RC</Initials>
            <AffiliationInfo>
              <Affiliation>11 National Institute for Health Research University College London Hospitals Biomedical Research Centre, London, United Kingdom.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>12 University College London Hospitals National Health Service Foundation Trust, London, United Kingdom.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Thirlwell</LastName>
            <ForeName>Michael</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>13 McGill University Health Centre, Montreal, Quebec, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Dolling</LastName>
            <ForeName>David</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>14 The Institute of Cancer Research, London, United Kingdom.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Morden</LastName>
            <ForeName>James</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>14 The Institute of Cancer Research, London, United Kingdom.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Snowdon</LastName>
            <ForeName>Claire</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>14 The Institute of Cancer Research, London, United Kingdom.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Perry</LastName>
            <ForeName>Sophie</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>14 The Institute of Cancer Research, London, United Kingdom.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cornman</LastName>
            <ForeName>Chester</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>15 National Surgical Adjuvant Breast and Bowel Project Foundation, Pittsburgh, PA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Batten</LastName>
            <ForeName>Leona M</ForeName>
            <Initials>LM</Initials>
            <AffiliationInfo>
              <Affiliation>14 The Institute of Cancer Research, London, United Kingdom.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jeffs</LastName>
            <ForeName>Lisa K</ForeName>
            <Initials>LK</Initials>
            <AffiliationInfo>
              <Affiliation>14 The Institute of Cancer Research, London, United Kingdom.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Dodson</LastName>
            <ForeName>Andrew</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>1 The Royal Marsden National Health Service Foundation Trust, London, United Kingdom.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>14 The Institute of Cancer Research, London, United Kingdom.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Martins</LastName>
            <ForeName>Vera</ForeName>
            <Initials>V</Initials>
            <AffiliationInfo>
              <Affiliation>1 The Royal Marsden National Health Service Foundation Trust, London, United Kingdom.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Modi</LastName>
            <ForeName>Arjun</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>1 The Royal Marsden National Health Service Foundation Trust, London, United Kingdom.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Osborne</LastName>
            <ForeName>C Kent</ForeName>
            <Initials>CK</Initials>
            <AffiliationInfo>
              <Affiliation>8 Baylor College of Medicine, Houston, TX.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pogue-Geile</LastName>
            <ForeName>Katherine L</ForeName>
            <Initials>KL</Initials>
            <AffiliationInfo>
              <Affiliation>15 National Surgical Adjuvant Breast and Bowel Project Foundation, Pittsburgh, PA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cheang</LastName>
            <ForeName>Maggie Chon U</ForeName>
            <Initials>MCU</Initials>
            <AffiliationInfo>
              <Affiliation>14 The Institute of Cancer Research, London, United Kingdom.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wolmark</LastName>
            <ForeName>Norman</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>15 National Surgical Adjuvant Breast and Bowel Project Foundation, Pittsburgh, PA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Julian</LastName>
            <ForeName>Thomas B</ForeName>
            <Initials>TB</Initials>
            <AffiliationInfo>
              <Affiliation>16 Allegheny Health Network Cancer Institute, Pittsburgh, PA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fisher</LastName>
            <ForeName>Kate</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>17 International Drug Development Institute, Brussels, Belgium.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>MacKenzie</LastName>
            <ForeName>Mairead</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>18 Independent Cancer Patients Voice, London, United Kingdom.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wilcox</LastName>
            <ForeName>Maggie</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>18 Independent Cancer Patients Voice, London, United Kingdom.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Huang Bartlett</LastName>
            <ForeName>Cynthia</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>19 Pfizer, New York, NY.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Koehler</LastName>
            <ForeName>Maria</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>20 Bicycle Therapeutics, Boston, MA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Dowsett</LastName>
            <ForeName>Mitch</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>1 The Royal Marsden National Health Service Foundation Trust, London, United Kingdom.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>14 The Institute of Cancer Research, London, United Kingdom.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bliss</LastName>
            <ForeName>Judith M</ForeName>
            <Initials>JM</Initials>
            <AffiliationInfo>
              <Affiliation>14 The Institute of Cancer Research, London, United Kingdom.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jacobs</LastName>
            <ForeName>Samuel A</ForeName>
            <Initials>SA</Initials>
            <AffiliationInfo>
              <Affiliation>15 National Surgical Adjuvant Breast and Bowel Project Foundation, Pittsburgh, PA.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>C1491/A15955</GrantID>
            <Acronym>CRUK_</Acronym>
            <Agency>Cancer Research UK</Agency>
            <Country>United Kingdom</Country>
          </Grant>
          <Grant>
            <Acronym>DH_</Acronym>
            <Agency>Department of Health</Agency>
            <Country>United Kingdom</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D017427">Clinical Trial, Phase II</PublicationType>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016448">Multicenter Study</PublicationType>
          <PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2018</Year>
          <Month>12</Month>
          <Day>06</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>J Clin Oncol</MedlineTA>
        <NlmUniqueID>8309333</NlmUniqueID>
        <ISSNLinking>0732-183X</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D047072">Aromatase Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D010879">Piperazines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D047428">Protein Kinase Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011725">Pyridines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011960">Receptors, Estrogen</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>7LKK855W8I</RegistryNumber>
          <NameOfSubstance UI="D000077289">Letrozole</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.10.1</RegistryNumber>
          <NameOfSubstance UI="C508053">ERBB2 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.10.1</RegistryNumber>
          <NameOfSubstance UI="D018719">Receptor, ErbB-2</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>G9ZF61LE7G</RegistryNumber>
          <NameOfSubstance UI="C500026">palbociclib</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D047072" MajorTopicYN="N">Aromatase Inhibitors</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017024" MajorTopicYN="N">Chemotherapy, Adjuvant</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004334" MajorTopicYN="N">Drug Administration Schedule</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000077289" MajorTopicYN="N">Letrozole</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020360" MajorTopicYN="N">Neoadjuvant Therapy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010879" MajorTopicYN="N">Piperazines</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017698" MajorTopicYN="N">Postmenopause</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D047428" MajorTopicYN="N">Protein Kinase Inhibitors</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011725" MajorTopicYN="N">Pyridines</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018719" MajorTopicYN="N">Receptor, ErbB-2</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011960" MajorTopicYN="N">Receptors, Estrogen</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2018</Year>
          <Month>12</Month>
          <Day>14</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2019</Year>
          <Month>10</Month>
          <Day>30</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2018</Year>
          <Month>12</Month>
          <Day>8</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">30523750</ArticleId>
        <ArticleId IdType="doi">10.1200/JCO.18.01624</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
